Latest News

Weekly News Roundup | 26 October 2026

Weekly News Roundup | 26 October 2026

Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

read more

Latest News

CBD Vaping: When Product Innovation Outpaces the Science

CBD Vaping: When Product Innovation Outpaces the Science

Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

From Flower to Pharmacy: The Science Behind Manuka Honey

From Flower to Pharmacy: The Science Behind Manuka Honey

Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...

read more
Weekly News Roundup | 23 March 2026

Weekly News Roundup | 23 March 2026

Your essential life science news  23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...

read more
Clinical Trials Roundup

Clinical Trials Roundup

This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...

read more
Power Outages as a Clinical Risk Multiplier in Healthcare

Power Outages as a Clinical Risk Multiplier in Healthcare

Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...

read more
The Physician Gap That’s Slowing Life Sciences

The Physician Gap That’s Slowing Life Sciences

We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...

read more
Protecting R&D and Clinical Trial Data in the Age of AI

Protecting R&D and Clinical Trial Data in the Age of AI

Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...

read more
Medical Writers Become Strategic Partners

Medical Writers Become Strategic Partners

In regulated drug development, documentation shapes how a program is understood long before regulators ever see it. Protocols, investigator brochures, integrated summaries, and submission-ready modules establish the scientific and strategic narrative of a development...

read more
From Flower to Pharmacy: The Science Behind Manuka Honey

From Flower to Pharmacy: The Science Behind Manuka Honey

Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...

read more
Weekly News Roundup | 23 March 2026

Weekly News Roundup | 23 March 2026

Your essential life science news  23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...

read more
Clinical Trials Roundup

Clinical Trials Roundup

This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...

read more
Power Outages as a Clinical Risk Multiplier in Healthcare

Power Outages as a Clinical Risk Multiplier in Healthcare

Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...

read more
The Physician Gap That’s Slowing Life Sciences

The Physician Gap That’s Slowing Life Sciences

We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...

read more
Protecting R&D and Clinical Trial Data in the Age of AI

Protecting R&D and Clinical Trial Data in the Age of AI

Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...

read more
Medical Writers Become Strategic Partners

Medical Writers Become Strategic Partners

In regulated drug development, documentation shapes how a program is understood long before regulators ever see it. Protocols, investigator brochures, integrated summaries, and submission-ready modules establish the scientific and strategic narrative of a development...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 16 March 2026

Weekly News Roundup | 16 March 2026

Your essential life science news digest: the past week's biggest stories in pharma, biotech and healthcare. 👇 This week's life science news was defined by regulatory uncertainty and clinical momentum. A landmark FDA leadership departure sent rare disease stocks...

read more
Reflections and Healing at the End of Life

Reflections and Healing at the End of Life

Words To Begin At age 81, the author has lived a "life of letters" (perhaps three million words) addressing a wide variety of subjects during multiple careers: Systems Engineering (PhD at UCLA in 1976), Military Science (21 years on active duty, in high-tech...

read more
The Microbiome: The Missing Layer in Modern Metabolic Care

The Microbiome: The Missing Layer in Modern Metabolic Care

Over the last decade, obesity management has undergone a structural transformation. What was once a field dominated almost exclusively by bariatric surgery has evolved into a far more nuanced metabolic discipline. The rise of GLP-1 receptor agonists and dual incretin...

read more
FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements

FDA Overhauls Pharmacokinetic Study Requirements in New Biosimilar Draft Guidance The US Food and Drug Administration (FDA) has overhauled biosimilar pharmacokinetic study requirements in new draft guidance issued on 9 March 2026, aimed at further reducing the time...

read more
Breakthroughs in the Lab – Blind Spots in Reality 

Breakthroughs in the Lab – Blind Spots in Reality 

Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....

read more

Further News

Ziltivekimab ZEUS Trial: What the Null Result Means

The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...

How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy

For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...

Singapore Radiopharmaceutical Market: How H2 2026 Looks

The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...

Why True Health Foods Need Evidence, Not Fashion

Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...

How Clinical Research Is Transforming the Future of Sarcoma Care

Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited...

Weekly News Roundup | 03 August 2026

Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...

Personalized Cancer Care: How the Immune System is Reshaping Oncology

Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear...

FDA PreCheck Program: Seven Companies Chosen to Reshape US Manufacturing

The United States Food and Drug Administration has selected seven pharmaceutical and biotechnology companies for its FDA PreCheck Program, a pilot initiative designed to accelerate the establishment of new domestic drug manufacturing facilities. Announced on 7 August...

Retatrutide Phase 3 Data: Record Weight Loss, Unanswered Questions

Retatrutide, Eli Lilly’s investigational triple hormone receptor agonist, has now reported positive results across five Phase 3 trials. In the pivotal TRIUMPH-1 obesity study, participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks,...

Responsible AI in Healthcare: Building Trust for Clinical Innovation

Artificial intelligence (AI) is rapidly transforming healthcare, moving beyond research laboratories into hospitals, clinics, and public health systems worldwide. Today, AI supports clinicians in areas such as medical imaging, clinical documentation, decision support,...

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...

Clinical Trials Roundup | 31 July 2026

An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.